Join Creoptix and 2bind for a virtual event to hear about the latest dynamics and trends in the molecular binding analysis field.
Expert in kinetics, Dr. Thomas Schubert from 2bind, will discuss the importance of reliable molecular binding characterization in antibody and small molecule development. Dr. Kaspar Cottier, founder of Creoptix and developer of the label-free GCI technology, will clarify the basis of the technology behind the WAVEsystem, a Creoptix technology and illustrate how it is being applied to accelerate discovery.
Together, our presenters will highlight the need for robust affinity and kinetics analysis in drug development and discuss the current solutions for life-science researchers.